Generics - UCB


Current filters:


Popular Filters

Advent and Avista acquire UCB’s generics subsidiary Kremers Urban

Advent and Avista acquire UCB’s generics subsidiary Kremers Urban


Global private equity investors Advent International and Avista Capital Partners have signed an agreement…

BelgiumGenericsKremers Urban PharmaceuticalsMergers & AcquisitionsUCB

Actavis confirms patent challenge for generic Neupro

Actavis confirms patent challenge for generic Neupro


Ireland-headquartered generics major Actavis on Friday confirmed that it has filed an Abbreviated New…


Actavis confirms Vimpat patent challenge and gets OK for generic Opana


US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

Impax Labs confirms patent challenge to Pfizer/UCB's Toviaz


US specialty drugmaker Impax Laboratories (Nasdaq: IPXL) yesterday confirmed that it has initiated a…

Gastro-intestinalsGenericsImpax LaboratoriesNorth AmericaPatentsPfizerToviazUCB

UCB buys majority stake in local drugmaker to expand in Brazil


Belgium's leading pharma company UCB (Euronext Brussels: UCB) says it has signed an agreement to acquire…

GenericsMeizler BiopharmaMergers & AcquisitionsPharmaceuticalSouth AmericaUCB

Opportunities for Pharma in narcolepsy


The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

Mylan debuts innovative version of levetiracetam


US generic drugmaker Mylan (Nasdaq: MYL) says that its Mylan Institutional business has launched Levetiracetam…

GenericsKeppraLevetiracetamMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaUCB

Back to top